2025 / 05

Next Paper
DOI: 10.24075/brsmu.2025.042
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Morphological, immunohistochemistry and molecular analysis of differentiated high-grade carcinoma

Makhachev DR, Bulanov DV, Shovkhalov MM, Bekmurziev BZ, Geroev IA, Netsvetova AM, Zhusupova AR, Gubich DS, Manovski AM
About authors

Pirogov Russian National Research Medical University (Pirogov University), Moscow, Russia

Correspondence should be addressed: Dalgat R. Makhachev
Akademika Volgina, 37, Moscow, 117437, Russia; ur.liam@2002taglad

About paper

Author contribution: FMakhachev DR, Bulanov DV, Shovkhalov MM, Bekmurziev BZ, Geroev IA — data analysis and interpretation, manuscript writing, editing; Netsvetova AM, Zhusupova AR — manuscript writing, editing; Gubich DS, Manovski AM — clinical data acquisition, editing.

Received: 2025-09-02 Accepted: 2025-09-15 Published online: 2025-09-24
|
  1. Rodrigo JP, Coca-Pelaz A, Agaimy A, Franchi A, Woolgar JA, Zafereo M, et al. Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact. Virchows Arch. 2024; 484 (2): 289– 304. Available from: https://doi.org/10.1007/s00428-024-03752-5.
  2. Cracolici V, Cipriani NA. High-grade non-anaplastic thyroid carcinomas of follicular cell origin: a review of poorly differentiated and high-grade differentiated carcinomas. Endocr Pathol. 2023; 34 (1): 29–45. Available from: https://doi.org/10.1007/s12022-023-09752-6.
  3. Resta IT, Montone KT, Livolsi VA. Differentiated high-grade thyroid carcinomas: diagnostic consideration and clinical features. Hum Pathol. 2024; 140: 1–9. Available from: https://doi.org/10.1016/j.humpath.2024.01.002.
  4. Duong MC, Nguyen LTT, Bhimani N, Thompson EK, Tufano RP, et al. Prognostic significance of key molecular markers in thyroid cancer: a systematic literature review and meta-analysis. Cancers (Basel). 2025; 17 (6): 939. Available from: https://doi.org/10.3390/cancers17060939.
  5. Thompson LDR. High-grade differentiated follicular cell-derived thyroid carcinoma versus poorly differentiated thyroid carcinoma: a clinicopathologic analysis of 41 cases. Endocr Pathol. 2023; 34 (1): 60–71. Available from: https://doi.org/10.1007/s12022-023-09770-4.
  6. Haq F, Bychkov A, Mete O, Kakudo K, Jung CK, et al. Identification of specific biomarkers for anaplastic thyroid carcinoma through spatial transcriptomic and immunohistochemical profiling. Endocr Pathol. 2025; 36 (1): 15–27. Available from: https://doi.org/10.1007/s12022-025-09858-z.
  7. Hernandez-Prera JC, Wenig BM. RAS-mutant follicular thyroid tumors: a continuous challenge for pathologists. Endocr Pathol. 2024; 35 (2): 98–110. Available from: https://doi.org/10.1007/s12022-024-09812-5.
  8. Chatterjee S, Mair M, Shaha AR, Paleri V, Sawhney R, et al. Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making. Endocrine. 2024; 79 (4): 680–96. Available from: https://doi.org/10.1007/s12020-024-03771-x.
  9. Yu HW, Jeong SI, Kim W, Choi JY, Ahn CH, et al. Incidence and clinicopathological features of differentiated high-grade thyroid carcinomas: an institutional experience. Endocr Pathol. 2023; 34 (2): 210–9. Available from: https://doi.org/10.1007/s12022-023-09778-w.
  10. Nkosi D, Crowe WE, Altman BJ, Oltvai ZN, Nikiforov YE. SATB2 is an emergent biomarker of anaplastic thyroid carcinoma: a series with comprehensive biomarker and molecular studies. Endocr Pathol. 2024; 35: 88–101. Available from: https://doi.org/10.1007/s12022-024-09833-0.
  11. Scholfield DW, Xu B, Levyn H, Eagan A, Shaha AR, et al. High-grade follicular cell-derived non-anaplastic thyroid carcinoma: correlating extent of invasion and mutation profile with oncologic outcome. Thyroid. 2025; 35 (2): 153–65. Available from: https://doi.org/10.1089/thy.2024.0499.
  12. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023; 29 (5): 1103– 12. Available from: https://doi.org/10.1038/s41591-023-02321-8.
  13. Hassan FA, Slone C, McDonald RJ, Dueber JC, Jha KK, et al. Folliculin (FLCN) in thyroid tumors: incidence, significance, and role as a driver gene and secondary alteration. Curr Oncol. 2025; 32 (4): 224. Available from: https://doi.org/10.3390/curroncol32040224.
  14. Wang Y, Zhang L, Liu Z. Molecular classification of thyroid tumors and key molecular features to identify high-grade thyroid carcinomas. In: Faquin WC, Bongiovanni M, editors. Thyroid FNA cytology: differential diagnoses and pitfalls. Singapore: Springer, 2024; p. 239–248. Available from: https://doi.org/10.1007/978-981-99-6782-7_21.
  15. Tan G, Jin B, Qian X, Li Y, Zhao H, et al. TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine-refractory differentiated thyroid cancer. Sci Rep. 2024; 14: 75087. Available from: https://doi.org/10.1038/s41598-024-75087-9.